StockData
Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc (IONS) stock

IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/303% below fair value
$26.96−1.05 (-3.75%)

Close on Nov 17, 2026Market cap $4.48BP/E –Yield –

Earnings

Ionis Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$243.00M
+54.8% on a year earlier
EPS, Q3 FY2026
-$0.66
-$0.80 a year earlier
Latest guidance
Raised
Nov 9, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Ionis Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026before the open$243.00M+54.8%-$0.66Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026before the open$268.00M-40.7%-$0.69Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026before the open$203.00M–-$1.41Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025before the open$157.00M–-$0.80Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025during market hours$452.00M+100.9%$0.70Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025during market hours–––Release
Q4 FY2024ended Dec 31, 2024Feb 19, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024during market hours$225.00M+19.7%-$0.45Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$119.00M-9.2%-$0.98Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Ionis Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
product salesFY2026$100.00M – $110.00M–NewJul 29, 2026
TRYNGOLZA product sales, netFY2026$50.00M$800.00M – $825.00MLoweredNov 9, 2026
Operating loss on a non-GAAP basisnon-GAAPFY2026$425.00M – $475.00M$500.00M – $550.00MLoweredNov 9, 2026
Cash, cash equivalents and short-term investmentsFY2026$1.60B$1.60MRaisedNov 9, 2026

Guidance history

Every forecast Ionis Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 9, 2026Operating loss on a non-GAAP basisFY2026$425.00M – $475.00MLowered
Nov 9, 2026Cash, cash equivalents and short-term investmentsFY2026$1.60BRaised
Nov 9, 2026TRYNGOLZA product sales, netFY2026$50.00MLowered
Nov 9, 2026DAWNZERA product sales, netFY2026$110.00M – $120.00MRaised
Nov 9, 2026Total RevenueFY2026$875.00M – $900.00MRaised
Jul 29, 2026product salesFY2026$100.00M – $110.00MNew
Jul 29, 2026product salesFY2026$110.00M – $120.00MRaised
Feb 25, 2026Operating loss on a non-GAAP basisFY2026$500.00M – $550.00MNew
Feb 25, 2026Cash, cash equivalents and short-term investmentsFY2026$1.60MNew
Feb 25, 2026RevenueFY2026$800.00M – $825.00MNew
Oct 29, 2025Operating loss on a non-GAAP basisFY2025-$300.00M – -$275.00MNew
Oct 29, 2025Cash, cash equivalents and short-term investmentsFY2025$2.10BNew
Oct 29, 2025Total RevenueFY2025$875.00M – $900.00MNew
Oct 29, 2025TRYNGOLZA product sales, netFY2025$85.00M – $95.00MLowered
Jul 30, 2025Operating loss on a non-GAAP basisFY2025$300.00M – $325.00MLowered
Jul 30, 2025Cash, cash equivalents and short-term investmentsFY2025$2.00BRaised
Jul 30, 2025TRYNGOLZA product sales, netFY2025$75.00M – $80.00MLowered
Jul 30, 2025Total RevenueFY2025$825.00M – $850.00MRaised
Apr 30, 2025Operating loss on a non-GAAP basisFY2025$375.00MNew
Apr 30, 2025Cash, cash equivalents and short-term investmentsFY2025$1.90BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Ionis Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Update
  5. Update
  6. Update
  7. Results
  8. Update
  9. Update
  10. Update
  11. Update
  12. Results
  13. Update
  14. Update
  15. Results

See a number that looks wrong?